Valley Medical Pharmacy 
630 Main Street 
Brawley, CA 92227 
eRx ID#0585957 
1 (800) 322-0808 | Toll Free Fax: 1 (855) 322-0808 
Email: drugsdepot@yahoo.com 
Web: www.drugsdepot 
Timing: Monday to Friday | 9:00 AM to 5:45 PM 


Menu
Image 0 of Amturnide Tab 30 by Novartis Pharma 300-10-25Image 1 of Amturnide Tab 30 by Novartis Pharma 300-10-25Image 2 of Amturnide Tab 30 by Novartis Pharma 300-10-25

Amturnide Tab 30 by Novartis Pharma 300-10-25

Call for Price

This Item Requires A Valid Order From A Physician Licensed in The USA. Item No.:Item Profile
Item No.RXD4369377/RXB10091574
Ndc 00078061415
Generic Name Aliskiren/Amlodipine/Hctz
Trade Name Amturnide
Additional Description
Strength 300-10-25Mg
Form Tabs
Size 30 Ea
Unit Of Measure Ea
Unit Of Sale Ea
Unit Dose
Schedule No. 0
Private Label 999
Multi-Source N
Active Status Active
Generic Ind. Branded Drug
Drug Class Rx
Vendor Name Novartis Pharmaceut

Have a question?

  Call for Price

Click Here for Prescribing Information



WARNING: AVOID USE IN PREGNANCY
When pregnancy is detected, discontinue Amturnide as soon as possible. Drugs that act directly on the reninangiotensin-
aldosterone system can cause injury and even death to the developing fetus [see Warnings and
Precautions (5.1) and Use in Specific Populations (8.1)].
1 INDICATIONS AND USAGE
Amturnide is indicated for the treatment of hypertension.
This fixed combination drug is not indicated for initial therapy of hypertension.
2 DOSAGE AND ADMINISTRATION
2.1 General Considerations
Dose once-daily. The dosage may be increased after 2 weeks of therapy. The maximum recommended dose of Amturnide
is 300/10/25 mg.
2.2 Add-on/Switch Therapy
Use Amturnide for patients not adequately controlled with any two of the following: aliskiren, dihydropyridine calcium
channel blockers, and thiazide diuretics.
Switch a patient who experiences dose-limiting adverse reactions attributed to an individual component?while on any
dual combination of the components of Amturnide?to Amturnide at a lower dose of that component to achieve similar
blood pressure reductions.
2.3 Replacement Therapy
For patients receiving aliskiren, amlodipine and HCTZ from separate tablets, substitute Amturnide containing the same
component doses.
2.4 Relationship to Meals
Patients should establish a routine pattern for taking Amturnide, either with or without a meal. High-fat meals decrease
absorption of aliskiren substantially [see Clinical Pharmacology (12.3)].
2.5 Dosing in Specific Populations
Renal Impairment
The usual regimens of Amturnide may be followed as long as the patient?s creatinine clearance is >30 mL/min. In patients
with more severe renal impairment, loop diuretics are preferred to thiazides, so Amturnide is not recommended [see
Warnings and Precautions (5.5)].
Hepatic Impairment
In patients with severe hepatic impairment, start amlodipine at 2.5 mg per day, a dose that is not available in Amturnide
[see Warnings and Precautions (5.6)].
Elderly Patients
Patients ≥ 75 years of age should start amlodipine at 2.5 mg, which is not available with Amturnide.
3 DOSAGE FORMS AND STRENGTHS
Tablets are convex ovaloid with a beveled edge, film-coated, and unscored, in the following strengths:
Aliskiren/Amlodipine/HCTZ
(mg)
Color Embossing
Side 1/side 2
150/5/12.5 Violet white YIY/NVR
300/5/12.5 Light pink LIL/NVR
300/5/25 Pale orange brown OIO/NVR
300/10/12.5 Light red UIU/NVR
300/10/25 Brown VIV/NVR
4 CONTRAINDICATIONS
Amturnide is contraindicated in patients with anuria or hypersensitivity to sulfonamide-derived drugs like HCTZ [see
Warnings and Precautions (5.8) and Adverse Reactions (6.1)]. Hypersensitivity reactions may range from urticaria to
anaphylaxis.